Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
about
Treatment strategies for radioactive iodine-refractory differentiated thyroid cancerHeme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.Pediatric Osteosarcoma: An Updated ReviewSorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.Residual renal function after partial or radical nephrectomy for renal cell carcinoma.Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry.Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumorsSafety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer.Delphinidin suppresses ultraviolet B-induced cyclooxygenases-2 expression through inhibition of MAPKK4 and PI-3 kinase.Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.Targeting angiogenesis in childhood sarcomas.The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.Sorafenib and thyroid cancer.Mechanistic insights on the Pd-catalyzed addition of C-X bonds across alkynes - a combined experimental and computational study.Dehydroglyasperin C suppresses TPA-induced cell transformation through direct inhibition of MKK4 and PI3K.Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cellsSignificant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.Molecular characterization of clear cell renal cell carcinoma identifies CSNK2A1, SPP1 and DEFB1 as promising novel prognostic markers.Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy.Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers.Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.Quantitation of sunitinib, an oral multitarget tyrosine kinase inhibitor, and its metabolite in urine samples by nonaqueous capillary electrophoresis time of flight mass spectrometry.Sorafenib in the treatment of thyroid cancer.
P2860
Q26862841-D63FD2A2-78DA-4497-B085-07E9322C5869Q27853203-D09E9187-36CA-408C-BED5-14CB734938EBQ30250106-FE4467CD-A125-4DE9-A26A-164A424A10E7Q33403207-6E8F2BF2-11A0-4C05-A7E9-CE146F013B8CQ33433070-15E454A2-3541-4A7C-AE70-BF53A16B897CQ33583291-B95177C9-132D-41CE-A8FE-0C8DEE275028Q34042709-10D9C74F-611F-4BD7-9487-F5ADD0FD2934Q34179292-8890F1C9-C45D-4090-A429-578A09E2F288Q34207858-F81B663A-39FD-4124-B6D7-AB4DDAD62334Q34460026-91854D6D-4123-40D3-AC2C-4380496CDC94Q34616563-C63C8B6A-D91D-4F9E-AD91-F9DA53DDF05FQ35998718-D63D3F27-D92E-45CC-8261-820BAB08ACCFQ36212825-B5DB3C0C-A731-4AA8-80BB-1863A563BBE0Q37269716-D08D5D9F-A9A9-4CD2-A959-EFBA7470B504Q37437242-90F2F2E2-E004-4D63-84EF-5FF7A65991B2Q37765584-43CBC816-F1BD-41C3-9D60-8B1EC916A24CQ37825441-DF13B473-8C3D-4EA1-8984-640A46728448Q37851857-0FCD4078-2C05-4D65-97AF-7A99027FA66BQ38118647-B40AD8AF-3CEC-4D0E-AEEC-9F6F2B98AA94Q38815698-FA931202-5F10-432C-8417-D9A279E59DDAQ38897786-64F7A07F-ACE7-40AE-AEC9-97CFB6D4B21DQ39500289-4F2FD12A-2C10-40F4-BB12-AD2BF305F698Q39677393-9B3C2BE7-3C0B-469B-A23A-2C781D10F31AQ39996613-7E8DC8EC-3250-4125-B831-C76CDEF05123Q39997736-58DB216A-A40E-44DF-844F-F6DEB1918082Q43179458-93DCE917-2216-42A3-A1DC-5824F973A616Q46542862-3BF5C4C5-A1DC-4B9E-97E1-C43D5B8047AEQ48090720-E8C8CC87-7643-49A6-96ED-C7F6832FACD6Q52654231-7ADC82B7-30D5-4A69-81F3-6FF712C05971Q53542598-6B420697-73FF-4AC8-A612-2B65893FFFB0Q55053748-F0597BB1-4080-4BEF-A69B-90BB45255519
P2860
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
@en
type
label
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
@en
prefLabel
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
@en
P2860
P356
P1433
P1476
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
@en
P2093
Barry R Goldspiel
Cheryl A Grandinetti
P2860
P304
P356
10.1592/PHCO.27.8.1125
P407
P577
2007-08-01T00:00:00Z